Filing Flows

Filing Flows › Moderna (MRNA) › Next earnings date

Moderna (MRNA) earnings: beat the estimate

Moderna (MRNA) reported on Nov 6, 2026 and beat the EPS estimate: $0.38 against −$1.25 (+130.3%). Revenue was $1.3B for Q3 2026, +29% year over year. It beat the EPS estimate in 100% of the quarters on record.

Last result+130.3% vs estimate
Beat rate100%

The last report

Moderna reported revenue of $1.3B for the third quarter 2026 (+29% Y/Y), net earnings $162M: Net product sales $1.3B, RSV $29.0M, Collaboration Arrangement, Including Arrangements with Affiliate $8.0M. How it makes money → · Every quarter →

Moderna: EPS against the estimate, last 5 reportsModerna: EPS against the estimate, last 5 reportsEstimateReported−$2.18−$0.51Nov 25−$2.60−$2.11Feb 26−$3.88−$3.40May 26−$2.06−$1.97Jul 26−$1.25$0.38Nov 26
Latest (Nov 26): Estimate −$1.25, Reported $0.38.
MRNA: the stock's move on each reportMRNA: the stock's move on each reportJul 31, 2026-4.8%May 1, 2026+3.0%Feb 13, 2026+9.5%Nov 6, 2025+4.2%

Moderna's latest quarter

Moderna, Q3 2026: revenue $1.3B (+29% year over year), operating margin 9.9%, net earnings $162M, operating cash flow −$1.6B. The chart follows the revenue to costs, profit and cash.

Questions

Did Moderna beat earnings?

Moderna (MRNA) reported on Nov 6, 2026 and beat the EPS estimate: $0.38 against −$1.25 (+130.3%).

When does MRNA report earnings?

The next date is not set yet.

Does Moderna usually beat earnings?

It beat the consensus EPS estimate in 100% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.